Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Targeted Therapies Patient Forum September 2017 Speaker Highlight - Sara Whitlock
Author
Denise Brock

***Speaker Highlights***

for full faculty bio's, please visit our FACULTY page


 

Learn about Sara Whitlock, RET + Patient

 

Sara was diagnosed with stage IV RET+ lung cancer in 2010. Traditional chemo and radiation followed with great success. In the years since Sara has been on and off treatment several times. She is currently taking nivolumab and doing very well. Sara lives in Dayton, OH with her husband, JD, and two daughters Katie and Elena. Katie just headed off to college at Washington University in St. Louis while Elena is in the 10th grade. Sara has been an active advocate for the lung cancer community doing both fundraising, grant review, and she is a patient advocate for the Alliance for Clinical Trials in Oncology. She is living proof that life doesn't stop with a stage IV diagnosis!  

 


 

 

 


Targeted Therapies in Lung Cancer Patient Forum
September 16, 2017

Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center

See below for our growing list of topics and presenters!  

Register at cancerGRACE.org | Agenda is subject to change

8:30 – 10:00 am        The Many Faces of Progression
Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy
Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope
10:30 – noon       
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy? 
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West

BREAKOUT SESSIONS

1:00 – 2:30 pm     
 
Presentations by Lung Cancer Sub-type
*Available treatment options 
*Acquired resistance: How do you pick your next treatment? 
ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient

BREAKOUT SESSIONS

2:50 – 4:00 pm     
 
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center
Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program
Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger

 

 GRACE would like to thank the following companies for their support of this forum:

B-I for web           
Guardant

 

 

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on
Thank you for sharing
By LeviDrake on
Hi bluesun,I don't know of…
By JanineT GRACE … on